Clinical trial
Study of Transitioning From Alendronate to Denosumab
NCT00377819 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00377819 |
|---|---|
| Title | Study of Transitioning From Alendronate to Denosumab |
| Official title | A Randomized Study to Evaluate Safety and Efficacy of Transitioning Therapy From Alendronate to Denosumab (AMG 162) in Postmenopausal Women With Low Bone Mineral Density |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Postmenopausal Osteoporosis |
| Intervention type | Drug |
| Interventions | alendronate, Denosumab (AMG 162) |
| Enrollment | 504 |
| Start date | Sep 1, 2006 |
| Primary completion | Mar 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Sep 18, 2006 |
| Last update posted | Jul 11, 2011 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: